Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
JCR in Talks with AstraZeneca on COVID-19 Vaccine Solution Manufacturing
JCR Pharmaceuticals said on July 31 that it is starting discussions with AstraZeneca on the domestic manufacturing of vaccine solutions for AZD1222, the UK giant’s novel coronavirus vaccine being codeveloped with Oxford University. Specific plans including the timeline to start…
To read the full story
Related Article
- Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
- Health Minister Hails Domestic Production Plan for AstraZeneca Vaccine
February 8, 2021
- AstraZeneca Files COVID-19 Vaccine in Japan
February 5, 2021
- AstraZeneca, Japan Govt Ink Definitive Deal on COVID-19 Vaccine
December 11, 2020
- AstraZeneca Approached Us for Manufacturing of Coronavirus Vaccine Solution: JCR Exec
November 5, 2020
- AstraZeneca to Supply 120 Million Doses of COVID-19 Vaccine to Japan
August 11, 2020
- AstraZeneca Aims to Deliver100 Million Doses of Coronavirus Vaccine to Japan: CEO
July 21, 2020
- AstraZeneca in Talks with Daiichi Sankyo, Meiji Group on COVID-19 Vaccine Supplies in Japan
June 29, 2020
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- FRONTEO Taps Bayer Ex-Chair Eiki as Advisor
July 22, 2026
- JCR Grabs 1st Overseas Nod for Izcargo in UAE
July 22, 2026
- Carna Bio’s AML Drug Candidate Earns US Orphan Tag
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…